Purpose: To report the efficacy of reduced-fluence photodynamic therapy (PDT) combined with intravitreal ranibizumab for the treatment of nonproliferative macular telangiectasia (MacTel) type 2. Methods: Noncomparative, interventional, retrospective case series; 5 eyes of 4 patients were studied. Patients were treated with reduced-fluence PDT and intravitreal ranibizumab within 24 h. After initial treatment, follow-up was at least 12 months in all patients. Results: At baseline median logMAR (logarithm of the minimal angle of resolution) best-corrected visual acuity (BCVA) was 1.0 (range, 1.0-0.3). At 3 months of follow-up vision increased in 3 out of 5 eyes and median BCVA was 0.4 (range, 1.0-0.2). The gain of BCVA ranged from 6 lines to 1 line. Visual acuity remained stable in the other 2 study eyes. No eyes lost vision at 3 months of follow-up. At 12 months of follow-up median logMAR BCVA was 0.7 (range, 1.3-0.3). Two eyes had maintained their gain in BCVA compared to baseline. Two eyes lost vision compared to baseline and 1 eye showed unchanged visual acuity at 12 months of follow-up. Conclusion: A combination therapy with reduced-fluence PDT and intravitreal ranibizumab might be a valuable treatment option for eyes with progressive vision loss due to nonproliferative MacTel type 2.

Keywords:
Combination therapy, Reduced-fluence photodynamic therapy, Ranibizumab, Nonproliferative macular telangiectasia type 2
1.
Gass JD, Oyakawa RT: Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 1982;100:769-780.
2.
Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren T, Peto T, Holz FG, Scholl HP: Macular telangiectasia type 2. Prog Retin Eye Res, E-pub ahead of print.
3.
Gass JD, Blodi BA: Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 1993;100:1536-1546.
4.
Klein R, Blodi BA, Meuer SM, Myers CE, Chew EY, Klein BE: The prevalence of macular telangiectasia type 2 in the Beaver Dam eye study. Am J Ophthalmol 2010;150:55-62.
5.
Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B: Idiopathic macular telangiectasia. Arch Ophthalmol 2006;124:450-460.
6.
Charbel Issa P, van der Veen RL, Stijfs A, Holz FG, Scholl HP, Berendschot TT: Quantification of reduced macular pigment optical density in the central retina in macular telangiectasia type 2. Exp Eye Res 2009;89:25-31.
7.
Bottoni F, Eandi CM, Pedenovi S, Staurenghi G: Integrated clinical evaluation of type 2A idiopathic juxtafoveolar retinal telangiectasis. Retina 2010;30:317-326.
8.
Charbel Issa P, Berendschot TT, Staurenghi G, Holz FG, Scholl HP: Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci 2008;49:1172-1177.
9.
Chhablani JK, Narayanan R: Fundus autofluorescence patterns in type 2A idiopathic juxtafoveolar retinal telangiectasis. Eur J Ophthalmol 2012;22:398-403.
10.
Povazay B, Hofer B, Torti C, Hermann B, Tumlinson AR, Esmaeelpour M, Egan CA, Bird AC, Drexler W: Impact of enhanced resolution, speed and penetration on three-dimensional retinal optical coherence tomography. Opt Express 2009;17:4134-4150.
11.
Schmitz-Valckenberg S, Fan K, Nugent A, Rubin GS, Peto T, Tufail A, Egan C, Bird AC, Fitzke FW: Correlation of functional impairment and morphological alterations in patients with group 2A idiopathic juxtafoveal retinal telangiectasia. Arch Ophthalmol 2008;126:330-335.
12.
Charbel Issa P, Helb HM, Rohrschneider K, Holz FG, Scholl HP: Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci 2007;48:3788-3795.
13.
Finger RP, Charbel Issa P, Fimmers R, Holz FG, Rubin GS, Scholl HP: Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2. Invest Ophthalmol Vis Sci 2009;50:1366-1370.
14.
Powner MB, Gillies MC, Tretiach M, Scott A, Guymer RH, Hageman GS, Fruttiger M: Perifoveal Müller cell depletion in a case of macular telangiectasia type 2. Ophthalmology 2010;117:2407-2416.
15.
Tsurumi Y, Murohara T, Krasinski K, Chen D, Witzenbichler B, Kearney M, Couffinhal T, Isner JM: Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med 1997;3:879-886.
16.
Adamis AP, Shima DT: The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-118.
17.
Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK: Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609-614.
18.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
19.
Varma R, Bressler NM, Suner I, Lee P, Dolan CM, Ward J, Colman S, Rubio RG: Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the bravo and cruise trials. Ophthalmology 2012;119:2108-2118.
20.
Charbel Issa P, Holz FG, Scholl HP: Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 2007;114:1736-1742.
21.
Roller AB, Folk JC, Patel NM, Boldt HC, Russell SR, Abramoff MD, Mahajan VB: Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina 2011;31:1848-1855.
22.
Charbel Issa P, Finger RP, Kruse K, Baumuller S, Scholl HP, Holz FG: Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol 2011;151:876-886.
23.
De Lahitte GD, Cohen SY, Gaudric A: Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization. Am J Ophthalmol 2004;138:892-894.
24.
Alldredge CD, Garretson BR: Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003;23:113-116.
25.
Park DW, Schatz H, McDonald HR, Johnson RN: Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 1997;104:1838-1846.
26.
Maia OO Jr, Takahashi WY, Bonanomi MT, Nascimento VP, Melo CS: intravitreal triamcinolone injection in the treatment of idiopathic juxtafoveal telangiectasis. Arq Brasil Oftalmol 2006;69:941-944.
27.
Watzke RC, Klein ML, Folk JC, Farmer SG, Munsen RS, Champfer RJ, Sletten KR: Long-term juxtafoveal retinal telangiectasia. Retina 2005;25:727-735.
28.
Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R: Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994;101:1953-1961.
29.
Charbel Issa P, Finger RP, Holz FG, Scholl HP: Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol 2008;92:941-945.
30.
Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW: Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occludens 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999;274:23463-23467.
31.
Charbel Issa P, Troeger E, Finger R, Holz FG, Wilke R, Scholl HP: Structure-function correlation of the human central retina. PloS One 2010;5:e12864.
32.
Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT: Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67.
33.
Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA: Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PloS One 2008;3:e3554.
34.
Battaglia Parodi M, Da Pozzo S, Ravalico G: Photodynamic therapy in chronic central serous chorioretinopathy. Retina 2003;23:235-237.
35.
Schmidt-Erfurth U, Hasan T: Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195-214.
36.
Shanmugam MP, Agarwal M: RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. Indian J Ophthalmol 2005;53:61-63.
37.
Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U: Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002;240:748-757.
38.
Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, Viestenz A, Naumann GO: Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002;120:835-844.
39.
Kovach JL, Rosenfeld PJ: Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II. Retina 2009;29:27-32.
40.
Bringmann A, Iandiev I, Pannicke T, Wurm A, Hollborn M, Wiedemann P, Osborne NN, Reichenbach A: Cellular signaling and factors involved in Müller cell gliosis: neuroprotective and detrimental effects. Prog Retin Eye Res 2009;28:423-451.
41.
Bringmann A, Pannicke T, Biedermann B, Francke M, Iandiev I, Grosche J, Wiedemann P, Albrecht J, Reichenbach A: Role of retinal glial cells in neurotransmitter uptake and metabolism. Neurochem Int 2009;54:143-160.
42.
Wahlin KJ, Adler R, Zack DJ, Campochiaro PA: Neurotrophic signaling in normal and degenerating rodent retinas. Exp Eye Res 2001;73:693-701.
43.
Harada T, Harada C, Kohsaka S, Wada E, Yoshida K, Ohno S, Mamada H, Tanaka K, Parada LF, Wada K: Microglia-Müller glia cell interactions control neurotrophic factor production during light-induced retinal degeneration. J Neurosci 2002;22:9228-9236.
44.
Bringmann A, Reichenbach A: Role of Müller cells in retinal degenerations. Front Biosci 2001;6:E72-E92.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.